Answers are grounded in this paper and cite their sources.
This study aimed to develop and optimize silymarin-loaded tin-dioxide nanoparticles (SLM-SnO₂-NPs) using a Quality by Design (QbD) approach for targeted topical therapy against melanoma. Nanoparticles were synthesized by chemical co-precipitation and optimized using Central Composite Design, considering stannous chloride concentration and sonication time as critical factors. The optimized nanoparticles were characterized for particle size, polydispersity index, and entrapment efficiency. A xanthan gum-based gel was prepared for dermal delivery and evaluated for pH, viscosity, in vitro drug release, and ex vivo skin permeation. Cytotoxic potential was assessed on A-375 human melanoma cells, along with apoptosis induction, antioxidant activity, and subcellular localization using confocal microscopy. The optimized formulation exhibited a particle size of 102.5 nm, PDI of 0.62, and entrapment efficiency of 86.38 %. Incorporation into xanthan gum gel (pH 6.5; viscosity 1312.47 cP) provided a suitable dermal base. In vitro release and ex vivo permeation studies demonstrated enhanced drug release and higher skin retention compared to plain gel. Cytotoxicity assays revealed significant antiproliferative activity with 73.5 % apoptosis induction, exceeding that of cisplatin (55.9 %). Confocal microscopy confirmed mitochondrial localization, while antioxidant studies demonstrated 85.3 % radical scavenging activity. The rationally designed SLM-SnO₂-NPs-gel significantly improved drug release, stability, skin retention, and selective cytotoxicity in in vitro and ex vivo models, supporting its potential as a novel nanoplatform for topical melanoma therapy. Future in vivo studies are warranted to confirm therapeutic efficacy and safety prior to preclinical translation.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: